As for the molecular mechanism of drug resistance in CML cells, there are several primary types: BCR::ABL1 mutations, BCR::ABL1-independent resistance, abnormal intracellular transporter of Imatinib, and survival of CML stem cells [5–10]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.